Triplex is under clinical development by Helocyte Biosciences and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Triplex’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Triplex overview

Triplex is under development for the treatment of Cytomegalovirus (HHV-5) infections, CMV associated HIV, liver transplant, kidney transplant, cytomegalovirus infections associated with stem cell transplantation in pediatric patients, Hodgkin/Non-Hodgkin lymphoma, myelodysplastic syndrome, acute lymphocytic leukemia (acute lymphoblastic leukemia/lymphoblastic lymphoma), acute myeloid leukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, myelofibrosis, b-cell non-Hodgkin lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma and multiple myeloma. The vaccine candidate consists of inactivated, modified vaccinia ankara (MVA) viral vector encoding three herpesvirus cytomegalovirus (CMV) tumor-associated antigens (TAAs), including UL83 (pp65), UL123 (IE1) and UL122 (IE2). It is administered through intramuscular route. It was also under development for the treatment of glioblastoma multiforme and hematological tumors.

Helocyte Biosciences overview

Helocyte is a clinical-stage biopharmaceutical company developing novel immunotherapies for the prevention and treatment of cancer. The company is headquartered in New York City, New York, the US

For a complete picture of Triplex’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.